Chemically modified cytosine nucleoside triphosphate as well as preparation method and application thereof

By chemically synthesizing and chemically modifying cytosine nucleoside and nucleoside triphosphate, replacing or combining it with mRNA, the problem of low mRNA stability and translation efficiency in the prior art is solved, and efficient translation in cells and cells is achieved and stability have expanded the clinical application potential of mRNA.

CN119080855APending Publication Date: 2024-12-06SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310655937.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-05
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

There are fewer types of modified nucleic acids in existing mRNA modification technologies, which are difficult to improve the stability and translation efficiency of mRNA, limiting its potential for clinical applications.

Method used

Chemically modify cytosine nucleoside and chemically modify cytosine nucleoside triphosphate by chemical synthesis, replacing or combining natural cytosine nucleosides in mRNA, enhance the translation efficiency and stability of mRNA and reduce immunogenicity.

Benefits of technology

The high translation efficiency and stability of chemically modified mRNAs in cells and cells are achieved, providing new mRNA modification options, enhancing their potential in clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080855A_ABST
    Figure CN119080855A_ABST
Patent Text Reader

Abstract

The invention provides chemically modified cytosine nucleoside triphosphate as well as a preparation method and application thereof, which are characterized in that chemically modified cytosine nucleoside and chemically modified cytosine nucleoside triphosphate are synthesized by utilizing a chemical synthesis means; the chemically modified cytidine triphosphate is used for globally replacing natural cytidine triphosphate in mRNA or the chemically modified cytidine triphosphate and N1-methyl pseudouridine triphosphate are combined for replacing natural cytidine triphosphate in mRNA, so that the translation efficiency and the stability of the target mRNA are enhanced, the immunogenicity is reduced, and a supplement and a new choice are provided for an mRNA modification technology.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of nucleic acid modification, and in particular relates to a chemically modified cytosine triphosphate and a preparation method and application thereof. Background Art

[0002] mRNA vaccines have the advantages of short R&D and production cycles, relatively simple processes, and rapid large-scale production and preparation, and are of great value in responding to sudden infectious diseases, tumor vaccines, tumor immunotherapy, protein replacement therapy, etc. Therefore, the development of new chemically modified nucleotides and their application in mRNA drug synthesis and clinical application is of great significance for mRNA gene therapy or virus prevention and treatment.

[0003] The mRNA modification methods used in existing patents mainly use modified nucleosides existing in nature to replace conventional nucleosides, such as using pseudouridine and methyl pseudouridine to replace uridine. CN107090436B discloses a non-therapeutic method or in vitro method for reducing the immunogenicity of an in vitro synthesized RNA molecule obtained by in vitro transcription or a preparation of a gene therapy vector containing the RNA molecule to mammalian cells, wherein the replacement uridine contained in the RNA molecule is selected from modified nucleosides of pseudouridine, 1-methyl pseudouridine, 5-methyluridine, 5-methoxyuridine and 2-thiouridine. The types of naturally occurring modified bases are very limited, so the means that can be used to improve the properties of mRNA are limited.

[0004] The use of chemical means to synthesize non-natural modified nucleosides can greatly enrich the types and range of non-natural nucleosides and is also suitable for establishing structure-activity relationships, which is not available with naturally occurring modified bases.

[0005] CN112673106A discloses a click-modified mRNA, which relates to alkyne and / or azide-modified mRNA, and stabilizes RNA by introducing alkyne and / or azide-modified nucleotides. This modification can not only stabilize the target mRNA for in vitro application and subsequent administration to human patients, animals or plants, but also can easily attach detectable markers or functional groups.

[0006] CN114807154A discloses a modified nucleic acid and its application, wherein the modified nucleic acid includes uridine, cytosine, adenine, guanosine and chemically modified nucleosides; the chemically modified nucleosides include one or more of chemically modified uridine, chemically modified cytosine, chemically modified adenine and chemically modified guanosine. The modified nucleic acid of the invention has high stability, low immunogenicity and long half-life in vivo.

[0007] However, there are still few types of modified nucleic acids. Therefore, it is necessary to develop new non-natural modified nucleotides with novel structures and introduce them into mRNA to improve the stability of mRNA and enhance its translation activity, so as to achieve the goal of replacing, enriching or supplementing existing mRNA chemical modifications, thereby providing support for new chemical modifications and applications of mRNA. Summary of the invention

[0008] In view of the deficiencies in the prior art, the purpose of the present invention is to provide a chemically modified cytosine triphosphate and a preparation method and application thereof. The present invention uses chemical synthesis means to synthesize chemically modified cytosine and chemically modified cytosine triphosphate, and uses the chemically modified cytosine triphosphate for global replacement, or uses the chemically modified cytosine triphosphate in combination with N1-methyl pseudoguanosine triphosphate to replace the natural cytosine triphosphate in mRNA, so as to enhance the translation efficiency and stability of the target mRNA, reduce immunogenicity, and provide a supplement and new choice for mRNA modification technology.

[0009] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0010] In a first aspect, the present invention provides a chemically modified cytosine nucleoside, wherein the chemically modified cytosine nucleoside is selected from a compound having a structure as shown in Formula VIII, a salt thereof, or an isomer thereof:

[0011]

[0012] wherein R1 is selected from hydrogen, acetyl, halogen-substituted acetyl, propionyl, halogen-substituted propionyl, butyryl, halogen-substituted butyryl, valeryl, halogen-substituted valeryl, hexanoyl, halogen-substituted hexanoyl, octanoyl, decanoyl, benzoyl, 4-methoxybenzoyl or 4-nitrobenzoyl;

[0013] R2 is selected from hydrogen, methyl, methoxy, fluoro, chloro, bromo, iodo or nitrile;

[0014] R3 is selected from hydroxy, hydrogen, fluorine, methoxy, ethoxy or methoxymethyl ether.

[0015] In the present invention, the chemically modified cytosine nucleoside is selected from:

[0016] N4-propionyl cytidine, N4-butyryl cytidine, N4-pentanoyl cytidine, N4-hexanoyl cytidine, N4-octanoyl cytidine, N4-decanoyl cytidine, N4-p-nitrobenzoyl cytidine, 5-methyl-N4-butyryl cytidine, 5-methyl-N4-hexanoyl cytidine, 5-methyl-N4-benzoyl cytidine, 2'-fluoro-N4-acetyl cytidine, 2'-fluoro-N4-butyryl cytidine, 2'-fluoro-N4-hexanoyl cytidine, 2'-methoxy cytidine, 2'-ethoxy cytidine.

[0017] In a second aspect, the present invention provides a chemically modified cytosine triphosphate, wherein the chemically modified cytosine triphosphate is selected from a compound having a structure as shown in Formula I, a salt thereof, or an isomer thereof:

[0018]

[0019] wherein R1 is selected from hydrogen, acetyl, halogen-substituted acetyl, etc., propionyl, halogen-substituted propionyl, etc., butyryl, halogen-substituted butyryl, etc., valeryl, halogen-substituted valeryl, hexanoyl, halogen-substituted hexanoyl, octanoyl, decanoyl, benzoyl, 4-methoxybenzoyl or 4-nitrobenzoyl;

[0020] R2 is selected from hydrogen, methyl, methoxy, fluoro, chloro, bromo, iodo or nitrile;

[0021] R3 is selected from hydroxy, hydrogen, fluorine, methoxy, ethoxy or methoxymethyl ether.

[0022] In the present invention, the chemically modified cytosine triphosphate is selected from:

[0023] N4-acetylcytidine triphosphate, N4-propionylcytidine triphosphate, N4-butyrylcytidine triphosphate, N4-pentanoylcytidine triphosphate, N4-hexanoylcytidine triphosphate, N4-octanoylcytidine triphosphate, N4-decanoylcytidine triphosphate, N4-benzoylcytidine triphosphate, N4-p-methoxybenzoylcytidine triphosphate, N4-p-nitrobenzoylcytidine triphosphate, 5-methylcytidine triphosphate, 5- Methyl-N4-acetylcytidine triphosphate, 5-methyl-N4-butyrylcytidine triphosphate, 5-methyl-N4-hexanoylcytidine triphosphate, 5-methyl-N4-benzoylcytidine triphosphate, 2'-fluoro-N4-acetylcytidine triphosphate, 2'-fluoro-N4-butyrylcytidine triphosphate, 2'-fluoro-N4-hexanoylcytidine triphosphate, 2'-methoxycytidine triphosphate, 2'-ethoxycytidine triphosphate.

[0024] The present invention provides a new chemically modified cytosine triphosphate, which provides more available cytosine triphosphate for mRNA. The chemically modified cytosine triphosphate synthesized in the present invention can be used for the synthesis of mRNA, can replace natural cytosine, alone or in combination with other modified nucleotides, and can play a corresponding translation function, can enhance the translation efficiency and stability of the target mRNA, and reduce immunogenicity, providing a supplement and new choice for mRNA technology beyond the current patented technology.

[0025] In a third aspect, the present invention provides a method for preparing the chemically modified cytosine triphosphate according to the second aspect, the preparation method comprising:

[0026] (1) subjecting the hydroxyl group of the compound of formula II to a hydroxyl protection reaction to obtain a compound of formula III;

[0027] (2) reacting the compound of formula III with an acid anhydride or an acid chloride to obtain a compound of formula IV;

[0028] (3) subjecting the protecting group of the compound of formula IV to complete deprotection reaction to obtain a compound of formula V;

[0029] (4) reacting the compound of formula V with a chlorinating agent to obtain a compound of formula VI;

[0030] (5) reacting the compound of formula VI with tributylammonium pyrophosphate to obtain a compound of formula VII;

[0031] (6) subjecting the compound of formula VII to a quenching reaction to obtain a compound of formula I;

[0032]

[0033] Preferably, in step (1), tert-butyldimethylsilyl chloride is used to carry out the hydroxyl protection reaction.

[0034] In step (2), the acid anhydride is selected from acetic anhydride, propionic anhydride, butyric anhydride, valeric anhydride, caproic anhydride, caprylic anhydride, capric anhydride or benzoic anhydride.

[0035] In step (2), the acyl chloride is selected from 4-methoxybenzoyl chloride or 4-nitrobenzoyl chloride.

[0036] Preferably, in step (3), tetrabutylammonium fluoride is used to carry out a complete deprotection reaction.

[0037] Preferably, in step (4), the chlorination agent is selected from phosphorus oxychloride.

[0038] In a fourth aspect, the present invention provides a chemically modified nucleic acid, wherein the chemically modified nucleic acid adopts the global replacement of the chemically modified cytosine triphosphate described in the first aspect during the preparation process, or the chemically modified cytosine triphosphate and N1-methylpseudouridine triphosphate are used in combination to replace the natural cytosine triphosphate in mRNA.

[0039] Preferably, the nucleic acid further contains pseudouridine, N-methylpseudouridine, 5-methoxyuridine or 2-thiouridine.

[0040] The present invention synthesizes non-natural modified nucleotides with novel structures and introduces them into mRNA, thereby improving the stability of mRNA and enhancing its translation activity, achieving the goal of replacing, enriching or supplementing existing mRNA chemical modifications, thereby providing assistance for novel chemical modifications and applications of mRNA.

[0041] Preferably, the nucleic acid comprises at least:

[0042] A) a promoter sequence;

[0043] B) a 5'UTR containing at least one Kozak sequence;

[0044] C) 3'UTR;

[0045] D) a coding sequence consisting of linked nucleotides;

[0046] E) Poly A tail.

[0047] The present invention uses chemical synthesis to synthesize chemically modified cytosine triphosphates, and then uses transcriptase and / or tailing enzyme to synthesize modified mRNA with global replacement of modified cytosine. The modified mRNA exhibits enhanced translation efficiency and higher stability both in vitro and in cells.

[0048] In a fifth aspect, the present invention provides a method for preparing the chemically modified nucleic acid according to the fourth aspect, the preparation method comprising:

[0049] Using four ribonucleotides, adenosine triphosphate, guanosine triphosphate, uridine triphosphate and chemically modified cytosine triphosphate, as raw materials, PCR reaction is carried out with DNA as a template under the catalysis of RNA polymerase to synthesize chemically modified nucleic acids.

[0050] Preferably, the RNA polymerase is T7 RNA polymerase.

[0051] Preferably, the PCR reaction system includes: a DNA template, an RNase inhibitor, T7 RNA polymerase, an RNA polymerase buffer, adenosine triphosphate, guanosine triphosphate, uridine triphosphate, chemically modified cytosine triphosphate and a 5' cap structure.

[0052] In the present invention, the chemically modified nucleic acid is a modified mRNA in which chemically modified cytidine triphosphate is used to globally replace natural cytidine. The mRNA has a higher translation efficiency and is more stable both in a cell-free system and in cells. The technical route for the synthesis and translation of the mRNA is as follows Figure 1 shown.

[0053] In a sixth aspect, the present invention provides the use of any one or a combination of at least two of the chemically modified cytosine nucleoside described in the first aspect, the chemically modified cytosine triphosphate described in the second aspect, the method for preparing the chemically modified cytosine triphosphate described in the third aspect, the chemically modified nucleic acid described in the fourth aspect, or the method for preparing the chemically modified nucleic acid described in the fifth aspect in the preparation of mRNA drugs.

[0054] The numerical range described in the present invention not only includes the point values ​​listed above, but also includes any point values ​​between the above numerical ranges that are not listed. Due to space limitations and for the sake of simplicity, the present invention no longer exhaustively lists the specific point values ​​included in the range.

[0055] Compared with the prior art, the present invention has the following beneficial effects:

[0056] The present invention provides a new chemically modified cytidine and chemically modified cytidine triphosphate, which provides more available cytidine triphosphate for mRNA. The chemically modified cytidine triphosphate synthesized in the present invention can be used for the synthesis of mRNA, which can replace natural cytidine, and can play a corresponding translation function, which can enhance the translation efficiency and stability of the target mRNA, reduce immunogenicity, and provide a supplement and new choice for mRNA technology. The chemically modified mRNA of the present invention shows that the mRNA replaced by modified cytosine has a translation effect that reaches or exceeds the modification method of pseudouridine and methyl pseudouridine used in mRNA modification in the currently reported technology, and has good biological stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 It is a technical route for chemically modified mRNA synthesis and translation;

[0058] Figure 2 It is a technical roadmap for the preparation of chemically modified cytidine triphosphate;

[0059] Figure 3 N4-propionyl cytidine triphosphate 1 H NMR spectrum;

[0060] Figure 4 N4-propionyl cytidine triphosphate 31 P NMR spectrum;

[0061] Figure 5 is the mass spectrum of N4-propionylcytidine triphosphate;

[0062] Figure 6 N4-butyryl cytidine triphosphate 1 H NMR spectrum;

[0063] Figure 7 N4-butyryl cytidine triphosphate 31 P NMR spectrum;

[0064] Figure 8 is the mass spectrum of N4-butyryl cytidine triphosphate;

[0065] Fig. 9 N4-pentanoyl cytidine triphosphate 1 H NMR spectrum;

[0066] Fig.10 N4-pentanoyl cytidine triphosphate 31 P NMR spectrum;

[0067] Fig.11 is the mass spectrum of N4-pentanoylcytidine triphosphate;

[0068] Fig.12 N4-hexanoyl cytidine triphosphate 1 H NMR spectrum;

[0069] Fig.13 N4-hexanoyl cytidine triphosphate 31 P NMR spectrum;

[0070] Fig.14 is the mass spectrum of N4-hexanoyl cytidine triphosphate;

[0071] Fig.15 5-methyl-N4-acetylcytidine triphosphate 1 H NMR spectrum;

[0072] Fig.16 5-methyl-N4-acetylcytidine triphosphate 31 P NMR spectrum;

[0073] Fig.17 is the mass spectrum of 5-methyl-N4-acetylcytidine triphosphate;

[0074] Fig.18 5-methyl-N4-butyryl cytidine triphosphate 1 H NMR spectrum;

[0075] Fig.19 5-methyl-N4-butyryl cytidine triphosphate 31 P NMR spectrum;

[0076] Fig. 20 is the mass spectrum of 5-methyl-N4-butyryl cytidine triphosphate;

[0077] Fig.21 N4-benzoylcytidine triphosphate 1 H NMR spectrum;

[0078] Fig. 22 N4-benzoylcytidine triphosphate 31 P NMR spectrum;

[0079] Fig.23 N4-acetylcytidine triphosphate 1 H NMR spectrum;

[0080] Fig.24 N4-acetylcytidine triphosphate 31 P NMR spectrum;

[0081] Fig.25 is the mass spectrum of N4-acetylcytidine triphosphate;

[0082] Fig.26 5-methylcytidine triphosphate 1 H NMR spectrum;

[0083] Fig. 27 5-methylcytidine triphosphate 31 P NMR spectrum;

[0084] Fig.28 is the mass spectrum of 5-methylcytidine triphosphate;

[0085] Fig.29 5-methyl-N4-hexanoyl cytidine triphosphate 1 H NMR spectrum;

[0086] Fig.30 5-methyl-N4-hexanoyl cytidine triphosphate 31 P NMR spectrum;

[0087] Fig.31 is the mass spectrum of 5-methyl-N4-hexanoyl cytidine triphosphate;

[0088] Fig.32 N4-octanoyl cytidine triphosphate 1 H NMR spectrum;

[0089] Fig.33 N4-decanoylcytidine triphosphate 1 H NMR spectrum;

[0090] Fig.34 5-methyl-N4-benzoylcytidine triphosphate 1 H NMR spectrum;

[0091] Fig.35 2'-fluoro-N4-acetylcytidine triphosphate 1 H NMR spectrum;

[0092] Fig.36 2'-Fluoro-N4-butyryl cytidine triphosphate 1 H NMR spectrum;

[0093] Fig.37 2'-fluoro N4-hexanoyl cytidine triphosphate 1 H NMR spectrum;

[0094] Fig.38 It is a schematic diagram of the in vitro transcription results of chemically modified C series nucleoside triphosphates;

[0095] Fig.39 This is the expression efficiency diagram of transcribed mRNA transfected into HEK 293T cells 24 hours later;

[0096] Fig.40 This is the expression efficiency diagram of mRNA transcribed by N1-methyl pseudouridine and modified cytidine after transfection into HEK 293T cells for 24 hours;

[0097] Fig.41 This is the expression efficiency diagram of transcribed mRNA transfected into HEK 293T cells 24 hours later;

[0098] Fig.42 This is the expression efficiency diagram of mRNA transcribed by N1-methyl pseudouridine and modified cytidine after transfection into HeLa cells for 24 hours;

[0099] Fig.43 The qPCR results of the stability of chemically modified mRNA in HEK 293T cells are shown;

[0100] Fig.44 This is the qPCR result of the stability test of chemically modified mRNA in HeLa cells;

[0101] Fig.45Western blot results of the immunogenicity test of chemically modified mRNA in RAW264.7 cells. DETAILED DESCRIPTION

[0102] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0103] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0104] Example 1 Preparation method of chemically modified cytidine triphosphate

[0105] This embodiment provides a method for preparing chemically modified cytidine triphosphate. The preparation technology route of chemically modified cytidine triphosphate is as follows: Figure 2 The reaction conditions of each step are shown below, and the structure of the compound is characterized by nuclear magnetic resonance and mass spectrometry:

[0106] a. 3 mmol (1 eq) of cytidine was dissolved in 15 mL of N,N-dimethylformamide, and then 12 mmol (4 eq) of tert-butyldimethylsilyl chloride and 15 mmol (5 eq) of imidazole were added in sequence, and stirred at 25°C overnight; after the reaction, the reaction solution was extracted with 10 mL of ethyl acetate, and the reaction mixture was repeated 3 times, and the organic phase was washed with water, and the reaction mixture was repeated 3 times. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane / methanol = 100 / 1) to obtain a white solid compound 1 (i.e., a compound of formula III); the structure of compound 1 is as follows 1 H NMR, 13 C NMR and HRMS confirmed.

[0107] b. Dissolve 2 mmol (1 eq) of compound 1 in 15 mL of anhydrous pyridine, then add dropwise 1.2 eq of the corresponding acid anhydride, then add 10 mg of 4-dimethylaminopyridine, and stir overnight at 25 ° C; after the reaction, extract the reaction solution with 10 mL of ethyl acetate, repeat 3 times, wash the organic phase with water, repeat 3 times, collect the organic phase, dry it over anhydrous sodium sulfate, filter, concentrate, and purify it by silica gel column chromatography (dichloromethane / methanol = 200 / 1) to obtain a white colloidal compound 2 (i.e., compound IV); the structure of compound 2 is as follows 1 HNMR, 13 C NMR and HRMS confirmed.

[0108] c. Dissolve 1.5 mmol (1 eq) of compound 2 in 15 mL of anhydrous tetrahydrofuran, then dropwise add 4.5 mL (3 eq) of tetrabutylammonium fluoride solution (1 M tetrahydrofuran solution), stir at room temperature for 0.5 h, then concentrate under reduced pressure, and purify by silica gel column chromatography (dichloromethane / methanol = 20 / 1 to 10 / 1) to obtain a white solid compound 3 (i.e., compound V). The structure of compound 3 is 1 HNMR, 13 C NMR and HRMS confirmed.

[0109] d. Dissolve 0.1mmol of compound 3 in 2mL of anhydrous pyridine, and remove water by co-evaporation under reduced pressure for 3 times; under nitrogen protection, inject 1mL of dry trimethyl phosphate, and after the solid is completely dissolved, place the test tube in an ice bath to cool for 2min, and add 1.5eq of phosphorus oxychloride with a syringe; stir and react for 2.5h in an ice bath; then inject 1.5eq of dry tributylamine and 1.5mL (8eq) of tributylammonium pyrophosphate solution (0.5MN, N-dimethylformamide solution) in turn under ice bath conditions, and move to room temperature to react for 0.5h. After the reaction is completed, quench the reaction with 5mL of 2.0M saturated triethylamine-carbonic acid aqueous solution in an ice bath, then extract the reaction liquid with 10mL of dichloromethane, collect the aqueous phase, and repeat 4 times; separate and purify the collected aqueous phase with a rapid preparative liquid chromatograph C18 column, and use 50mM saturated triethylamine-carbonic acid aqueous solution and chromatographic grade acetonitrile as mobile phases; finally, freeze-dry the collected and purified solution to obtain white solid 4 (compound of formula I). ​​The structure of compound 4 is as follows 1 H NMR, 31 P NMR and HRMS confirmed.

[0110] In the method for preparing chemically modified cytidine triphosphate in this embodiment, only step a, step b and step c are performed to obtain the method for preparing chemically modified cytidine.

[0111] Example 2N4-Propionylcytidine triphosphate

[0112] This embodiment provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-propionyl cytidine triphosphate. The reaction conditions of each step of the preparation are as follows, and the structure of the compound is characterized by nuclear magnetic resonance and mass spectrometry:

[0113] a. Take 3mmol (1eq) of cytidine and dissolve it in 15mL of N,N-dimethylformamide, then add 12mmol (4eq) of tert-butyldimethylsilyl chloride and 15mmol (5eq) of imidazole in sequence, and stir at 25°C overnight; after the reaction, extract the reaction solution with 10mL of ethyl acetate, repeat 3 times, wash the organic phase with water, repeat 3 times, collect the organic phase, dry it over anhydrous sodium sulfate, filter, concentrate, and purify it by silica gel column chromatography (dichloromethane / methanol=100 / 1) to obtain a white solid compound 1 (i.e., compound III), with a yield of 95%; the structure of compound 1 has been 1 H NMR, 13 C NMR and HRMS confirmed.

[0114] b. Dissolve 2 mmol (1 eq) of compound 1 in 15 mL of anhydrous pyridine, then add 1.2 eq of propionic anhydride dropwise, then add 10 mg of 4-dimethylaminopyridine, and stir overnight at 25 ° C; after the reaction, extract the reaction solution with 10 mL of ethyl acetate, repeat 3 times, wash the organic phase with water, repeat 3 times, collect the organic phase, dry it over anhydrous sodium sulfate, filter, concentrate, and purify it by silica gel column chromatography (dichloromethane / methanol=200 / 1) to obtain a white colloidal compound 2 (i.e., compound IV), with a yield of 92%; the structure of compound 2 has been 1 H NMR, 13 C NMR and HRMS confirmed.

[0115] c. Dissolve 1.5 mmol (1 eq) of compound 2 in 15 mL of anhydrous tetrahydrofuran, then dropwise add 4.5 mL (3 eq) of tetrabutylammonium fluoride solution (1 M tetrahydrofuran solution), stir at room temperature for 0.5 h, then concentrate under reduced pressure, and purify by silica gel column chromatography (dichloromethane / methanol = 20 / 1 to 10 / 1) to obtain a white solid compound 3 (i.e., compound V). The structure of compound 3 has been 1 HNMR, 13 C NMR and HRMS confirmed.

[0116] d. Dissolve 0.1mmol of compound 3 in 2mL of anhydrous pyridine, and dehydrate under reduced pressure for 3 times; inject 1mL of dry trimethyl phosphate under nitrogen protection, place the test tube in an ice bath for 2min after the solid is completely dissolved, and add 1.5eq of phosphorus oxychloride dropwise with a syringe; stir and react for 2.5h under ice bath; then inject 1.5eq of dry tributylamine and 1.5mL (8eq) of tributyl ammonium pyrophosphate solution (0.5MN, N-dimethylformamide solution) in sequence under ice bath conditions, and move to room temperature for 0.5h. After the reaction is completed, quench the reaction with 5mL of 2.0M saturated triethylamine-carbonic acid aqueous solution under ice bath, then extract the reaction solution with 10mL of dichloromethane, collect the aqueous phase, and repeat 4 times; separate and purify the collected aqueous phase with a rapid preparative liquid chromatograph C18 column, and use 50mM saturated triethylamine-carbonic acid aqueous solution and chromatographic grade acetonitrile as mobile phases; finally, freeze-dry the collected purified solution to obtain white solid 4 (compound of formula I). The structure of compound 4 has been 1 H NMR, 31 P NMR and HRMS confirmed.

[0117] Figure 3 N4-propionyl cytidine triphosphate 1 H NMR spectrum. As can be seen from the figure, the peak positions (unit: ppm) are: 1.07, 1.09, 1.11; 2.44, 2.46, 2.48, 2.49; 4.27, 4.28, 4.30, 4.31, 4.32, 4.38, 4.40, 4.41; 5.92, 5.93; 7.29, 7.31; 8.39, 8.40. Figure 4 N4-propionyl cytidine triphosphate 31 P NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: -22.70, -22.57, -22.45; -11.48, -11.46, -11.35, -11.34; -6.53, -6.40; 19.45, 19.51, 19.57. Figure 5 This is the mass spectrum of N4-propionylcytidine triphosphate.

[0118] Example 3N4-Butyryl cytidine triphosphate

[0119] This embodiment provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-butyryl cytidine triphosphate. The reaction conditions of each step of the preparation are as follows, and the structure of the compound is characterized by nuclear magnetic resonance and mass spectrometry:

[0120] a. Take 3mmol (1eq) of cytidine and dissolve it in 15mL of N,N-dimethylformamide, then add 12mmol (4eq) of tert-butyldimethylsilyl chloride and 15mmol (5eq) of imidazole in sequence, and stir at 25°C overnight; after the reaction, extract the reaction solution with 10mL of ethyl acetate, repeat 3 times, wash the organic phase with water, repeat 3 times, collect the organic phase, dry it over anhydrous sodium sulfate, filter, concentrate, and purify it by silica gel column chromatography (dichloromethane / methanol=100 / 1) to obtain a white solid compound 1 (i.e., compound III), with a yield of 93%; the structure of compound 1 has been 1 H NMR, 13 C NMR and HRMS confirmed.

[0121] b. Dissolve 2 mmol (1 eq) of compound 1 in 15 mL of anhydrous pyridine, then add 1.2 eq of butyric anhydride dropwise, then add 10 mg of 4-dimethylaminopyridine, and stir overnight at 25 ° C; after the reaction, extract the reaction solution with 10 mL of ethyl acetate, repeat 3 times, wash the organic phase with water, repeat 3 times, collect the organic phase, dry it over anhydrous sodium sulfate, filter, concentrate, and purify it by silica gel column chromatography (dichloromethane / methanol=200 / 1) to obtain a white colloidal compound 2 (i.e., compound IV), with a yield of 92%; the structure of compound 2 has been 1 H NMR, 13 C NMR and HRMS confirmed.

[0122] c. Dissolve 1.5 mmol (1 eq) of compound 2 in 15 mL of anhydrous tetrahydrofuran, then dropwise add 4.5 mL (3 eq) of tetrabutylammonium fluoride solution (1 M tetrahydrofuran solution), stir at room temperature for 0.5 h, then concentrate under reduced pressure, and purify by silica gel column chromatography (dichloromethane / methanol = 20 / 1 to 10 / 1) to obtain a white solid compound 3 (i.e., compound V). The structure of compound 3 has been 1 HNMR, 13 C NMR and HRMS confirmed.

[0123] d. Dissolve 0.1mmol of compound 3 in 2mL of anhydrous pyridine, and remove water by co-evaporation under reduced pressure for 3 times; inject 1mL of dry trimethyl phosphate under nitrogen protection, place the test tube in an ice bath for 2min after the solid is completely dissolved, and add 1.5eq of phosphorus oxychloride dropwise with a syringe; stir and react for 2.5h under ice bath; then inject 1.5eq of dry tributylamine and 1.5mL (8eq) of tributylammonium pyrophosphate solution (0.5MN, N-dimethylformamide solution) in turn under ice bath conditions, and move to room temperature for 0.5h. After the reaction is completed, quench the reaction with 5mL of 2.0M saturated triethylamine-carbonic acid aqueous solution under ice bath, then extract the reaction liquid with 10mL of dichloromethane, collect the aqueous phase, and repeat 4 times; separate and purify the collected aqueous phase with a rapid preparative liquid chromatograph C18 column, and use 50mM saturated triethylamine-carbonic acid aqueous solution and chromatographic grade acetonitrile as mobile phases; finally, freeze-dry the collected and purified solution to obtain white solid 4 (compound of formula VI). The structure of compound 4 has been 1 H NMR, 31 P NMR and HRMS confirmed.

[0124] Figure 6 N4-butyryl cytidine triphosphate 1 H NMR spectrum. As can be seen from the figure, the peak positions (unit: ppm) are: 0.87, 0.89, 0.91; 1.59, 1.61, 1.63, 1.65; 2.41, 2.42, 2.44; 4.24, 4.27, 4.28, 4.30, 4.31, 4.32, 4.39, 4.40, 4.42; 5.92, 5.93; 7.28, 7.30; 8.39, 8.41. Figure 7 N4-butyryl cytidine triphosphate 31 P NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: -22.68, -22.56, -22.43; -11.47, -11.45, -11.34, -11.33; -6.46, -6.33; 19.52, 19.58. Figure 8 This is the mass spectrum of N4-butyryl cytidine triphosphate.

[0125] Example 4N4-Valerylcytidine triphosphate

[0126] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-pentanoyl cytidine triphosphate. The reaction conditions of each step of the preparation are referred to Example 1. The anhydride used in step b is valeric anhydride.

[0127] Fig. 9 N4-pentanoyl cytidine triphosphate 1H NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: 0.80, 0.82, 0.84; 1.26, 1.28; 1.52, 1.53, 1.55, 1.57, 1.59; 2.40, 2.42, 2.44; 4.21, 4.24, 4.25, 4.27, 4.28, 4.29, 4.35, 4.37, 4.38; 5.89, 5.90; 7.25, 7.27; 8.36, 8.38. Fig.10 N4-pentanoyl cytidine triphosphate 31 P NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: -22.69, -22.57, -22.44; -11.51, -11.49, -11.39, -11.36, -11.35, -11.32; -6.54, -6.41. Fig.11 This is the mass spectrum of N4-pentanoyl cytidine triphosphate.

[0128] Example 5N 4-hexanoyl cytidine triphosphate

[0129] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-hexanoyl cytidine triphosphate. The reaction conditions of each step of the preparation are referred to Example 1. The anhydride used in step b is hexanoic anhydride.

[0130] Fig.12 N4-hexanoyl cytidine triphosphate 1 H NMR spectrum. As can be seen from the figure, the peak positions (unit: ppm) are: 0.77, 0.79, 0.80; 1.23, 1.24; 1.56, 1.58, 1.60; 2.39, 2.41, 2.43; 4.24, 4.25, 4.28, 4.35, 4.37, 4.38; 5.90; 7.26, 7.28; 8.36, 8.38. Fig.13 N4-hexanoyl cytidine triphosphate 31 PNMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: -22.64, -22.51, -22.38; -11.45, -11.33; -6.50, -6.37. Fig.14 It is the mass spectrum of N4-hexanoyl cytidine triphosphate.

[0131] Example 6 5-Methyl-N4-acetylcytidine triphosphate

[0132] This embodiment provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 5-methyl-N4-acetyl cytidine triphosphate. The reaction conditions of each step of the preparation are referred to Example 1, except that the reaction starting material used is 5-methylcytidine, and the acid anhydride used in step b is acetic anhydride.

[0133] Fig.15 5-methyl-N4-acetylcytidine triphosphate 1 H NMR spectrum. As can be seen from the figure, the peak positions (unit: ppm) are: 2.06; 2.24, 2.25; 4.24, 4.25, 4.27, 4.28; 4.36, 4.37, 4.39; 5.89, 5.90, 5.91; 8.22, 8.30. Fig.16 5-methyl-N4-acetylcytidine triphosphate 31 P NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: -22.99, -22.86, -22.74; -11.77, -11.75, -11.65, -11.63; -8.19, -8.05; 19.42, 19.47, 19.53. Fig.17 This is the mass spectrum of 5-methyl-N4-acetylcytidine triphosphate.

[0134] Example 7 5-Methyl-N4-butyryl cytidine triphosphate

[0135] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 5-methyl-N4-butyryl cytidine triphosphate. The reaction conditions of each step of the preparation are as described in Example 1, except that the reaction starting material used is 5-methylcytidine, and the anhydride used in step b is butyric anhydride.

[0136] Fig.18 5-methyl-N4-butyryl cytidine triphosphate 1 H NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: 0.84, 0.86, 0.88; 1.56, 1.57, 1.59, 1.61; 2.03; 2.43, 2.45, 2.47; 4.19, 4.21, 4.24, 4.25, 4.25, 4.36, 4.37, 4.39; 5.87, 5.88; 8.22. Fig.19 5-methyl-N4-butyryl cytidine triphosphate 31 P NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: -22.74, -22.61, -22.48; -11.77, -11.76, -11.65, -11.63; -6.52, -6.39. Fig. 20This is the mass spectrum of 5-methyl-N4-butyryl cytidine triphosphate.

[0137] Example 8N4-Benzoylcytidine triphosphate

[0138] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-benzoyl cytidine triphosphate. The reaction conditions of each step of the preparation are as described in Example 1. The anhydride used in step b is benzoic anhydride.

[0139] Fig.21 N4-benzoylcytidine triphosphate 1 H NMR spectrum; as can be seen from the figure, the peak positions (unit: ppm) are: 4.28, 4.28, 4.29, 4.30, 4.31, 4.33, 4.34, 4.34, 4.35, 4.39, 4.41, 4.42; 5.96, 5.97; 7.43, 7.45, 7.51, 7.53, 7.55, 7.63, 7.65, 7.67; 7.87, 7.87, 7.89; 8.45, 8.47. Fig. 22 N4-benzoylcytidine triphosphate 31 P NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: -22.88, -22.75, -22.63; -11.51, -11.48, -11.46, -11.43, -11.38, -11.35, -11.34, -11.31; -7.88, -7.77.

[0140] Example 9N4-Acetylcytidine triphosphate

[0141] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-acetyl cytidine triphosphate. The reaction conditions of each step of the preparation are as described in Example 1. The anhydride used in step b is acetic anhydride.

[0142] Fig.23 N4-acetylcytidine triphosphate 1 H NMR spectrum. As can be seen from the figure, the peak positions (unit: ppm) are: 2.18; 4.24, 4.27; 4.28; 4.31, 4.31, 4.32, 4.39, 4.40, 4.41; 5.92, 5.93; 7.26, 7.27; 8.39, 8.41. Fig.24 N4-acetylcytidine triphosphate 31 P NMR spectrum. From the figure, it can be seen that the peak positions (unit: ppm) are: -22.68, -22.56, -22.43; -11.46, -11.34; -6.46, -6.33. Fig.25 This is the mass spectrum of N4-acetylcytidine triphosphate.

[0143] Example 10N4-p-Anisyl cytidine triphosphate

[0144] This embodiment provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-p-methoxybenzoyl cytidine triphosphate. The reaction conditions of each step of the preparation are referred to Example 1. The acyl chloride used in step b is p-methoxybenzoyl chloride (4-methoxybenzoyl chloride).

[0145] The obtained N4-p-methoxybenzoyl cytidine triphosphate was tested, and the nuclear magnetic resonance data were as follows: 1 H NMR (400MHz, D2O) δ9.93 (s, 1H), 8.94 (d, J = 0.8Hz, 1H), 7.95 (d, J = 2.4Hz, 2H), 7.03 (d, J = 2.8Hz, 2H), 5.85 (d, J = 2.0Hz, 1H), 5.53 (d, J = 4.4Hz, 1H), 4.04-4.57 (m, 7H), 4.20 (m, 4H), 3.81 (s, 3H).

[0146] Example 11N4-p-nitrobenzoylcytidine triphosphate

[0147] This embodiment provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-p-nitrobenzoyl cytidine triphosphate. The reaction conditions of each step of the preparation are referred to Example 1. The acyl chloride used in step b is p-nitrobenzoyl chloride (4-nitrobenzoyl chloride).

[0148] The obtained N4-p-nitrobenzoyl cytidine triphosphate was detected, and the nuclear magnetic resonance data were: 1 H NMR (400MHz, D2O) δ9.91 (s, 1H), 8.96 (d, J = 0.8Hz, 1H), 8.33 (d, J = 2.4Hz, 2H), 8.20 (d, J = 3.2Hz, 2H), 5.84 (d, J = 2.0Hz, 1H), 5.54 (d, J = 4.8Hz, 1H), 4.03-4.57 (m, 7H), 4.21 (m, 4H), 3.81 (s, 3H).

[0149] Example 12 5-Methylcytidine triphosphate

[0150] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 5-methylcytidine triphosphate. The reaction conditions of each step of the preparation are referred to Example 1, except that 5-methylcytidine is used as the starting reactant and the triphosphorylation reaction is directly carried out under the conditions of step d.

[0151] Fig.26 5-methylcytidine triphosphate 1 H NMR spectrum. As can be seen from the figure, the peak positions (unit: ppm) are: 1.91; 4.15, 4.16, 4.18; 4.23, 4.25, 4.26; 4.36, 4.37, 4.38; 5.91, 5.92; 7.73. Fig. 27 5-methylcytidine triphosphate 31 P NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: -23.09, -22.66, -22.54, -22.41; -11.68, -11.56; -7.53, -6.49, -6.36. Fig.28 This is the mass spectrum of 5-methylcytidine triphosphate.

[0152] Example 13 5-Methyl-N4-hexanoyl cytidine triphosphate

[0153] This embodiment provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 5-methyl-N4-hexanoyl cytidine triphosphate. The reaction conditions of each step of the preparation are referred to Example 1, except that the reaction starting material used is 5-methylcytidine, and the acid anhydride used in step b is hexanoic anhydride.

[0154] Fig.29 5-methyl-N4-hexanoyl cytidine triphosphate 1 H NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: 0.79, 0.80, 0.80, 0.82; 1.24, 1.25, 1.26; 1.60, 1.62; 2.06, 2.06; 2.49, 2.51, 2.52; 4.24, 4.25, 4.28, 4.28, 4.34, 4.35, 4.37; 5.90, 5.91; 8.22. Fig.30 5-methyl-N4-hexanoyl cytidine triphosphate 31 P NMR spectrum. From the figure, it can be seen that the peak positions (unit: ppm) are: -22.68, -22.56, -22.43; -11.73, -11.61; -6.49, -6.36. Fig.31 This is the mass spectrum of 5-methyl-N4-hexanoyl cytidine triphosphate.

[0155] Example 14N4-octanoylcytidine triphosphate

[0156] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-octanoyl cytidine triphosphate, and the reaction conditions of each step of the preparation are referred to Example 1. The anhydride used in step b is octanoic anhydride.

[0157] Fig.32 N4-octanoyl cytidine triphosphate 1 H NMR spectrum. As can be seen from the figure, the peak positions (unit: ppm) are: 0.74, 0.76, 0.78; 1.23, 1.32, 1.34, 1.56, 1.57, 1.59; 2.39, 2.41, 2.43; 4.24, 4.25, 4.26, 4.28, 4.29, 4.30; 5.89, 5.90; 7.24, 7.26, 7.27; 8.32, 8.34.

[0158] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is N4-decanoyl cytidine triphosphate, and the reaction conditions of each step of the preparation are referred to Example 1. The anhydride used in step b is decanoic anhydride.

[0159] Fig.33 N4-decanoylcytidine triphosphate 1 H NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: 0.73, 0.75, 0.76; 1.20, 1.22; 1.56, 1.57, 1.59; 2.40, 2.42, 2.44; 4.24, 4.26, 4.27, 4.28, 4.30; 5.89, 5.90; 7.19, 7.21; 8.36, 8.38.

[0160] Example 16 5-Methyl-N4-benzoylcytidine triphosphate

[0161] This embodiment provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 5-methyl-N4-benzoyl cytidine triphosphate, and the reaction conditions of each preparation step refer to those of Example 1, except that the reaction starting material used is 5-methylcytidine, and the acid anhydride used in step b is benzoic anhydride.

[0162] Fig.34 5-methyl-N4-benzoylcytidine triphosphate 1 H NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: 2.10; 4.24, 4.25, 4.27, 4.28, 4.31, 4.32, 4.33, 4.41, 4.42, 4.43; 5.92, 5.93; 7.47, 7.49, 7.51, 7.59, 7.61, 7.63; 7.86, 7.88; 8.24.

[0163] Example 17 2'-Fluoro-N4-acetylcytidine triphosphate

[0164] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 2'-fluoro-N4-acetyl cytidine triphosphate. The reaction conditions of each preparation step refer to Example 1, except that the reaction starting material used is 2'-fluorocytidine, and the acid anhydride used in step b is acetic anhydride.

[0165] Fig.35 2'-fluoro-N4-acetylcytidine triphosphate 1 H NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: 2.14; 4.22, 4.24, 4.25, 4.28, 4.30, 4.33, 4.36, 4.40, 4.41, 4.42, 4.44, 4.47, 4.48, 4.49, 4.50; 4.98, 4.99; 5.11, 5.12; 5.98, 6.02; 7.23, 7.25; 8.35, 8.37.

[0166] Example 18 2'-Fluoro-N4-butyryl cytidine triphosphate

[0167] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 2'-fluoro-N4-butyryl cytidine triphosphate. The reaction conditions of each preparation step refer to Example 1, except that the reaction starting material used is 2'-fluorocytidine, and the anhydride used in step b is butyric anhydride.

[0168] Fig.36 2'-Fluoro-N4-butyryl cytidine triphosphate 1 H NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: 0.83, 0.84, 0.86; 1.55, 1.56, 1.58, 1.60; 2.36, 2.38, 2.40; 4.22, 4.24, 4.27, 4.28, 4.30, 4.33, 4.36, 4.40, 4.41, 4.43, 4.43, 4.47, 4.48, 4.49, 4.50; 4.98, 4.99; 5.11, 5.12; 5.98, 6.02; 7.25, 7.27; 8.34, 8.36.

[0169] Example 19 2'-Fluoro-N4-hexanoyl cytidine triphosphate

[0170] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 2'-fluoro-N4-hexanoyl cytidine triphosphate. The reaction conditions of each preparation step refer to those of Example 1, except that the reaction starting material used is 2'-fluorocytidine, and the acid anhydride used in step b is hexanoic anhydride.

[0171] Fig.372'-fluoro N4-hexanoyl cytidine triphosphate 1 H NMR spectrum. From the figure, we can see that the peak positions (unit: ppm) are: 0.76, 0.77, 0.79; 1.22, 1.22; 1.54, 1.56, 1.58; 2.38, 2.40, 2.41; 4.22, 4.25, 4.27, 4.34, 4.37, 4.39, 4.40, 4.41, 4.42, 4.46, 4.47, 4.48, 4.49; 4.98, 4.99; 5.11, 5.12; 5.98, 6.02; 7.26, 7.27; 8.33, 8.36.

[0172] Example 20 2'-Methoxycytidine triphosphate

[0173] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 2'-methoxycytidine triphosphate. The reaction conditions of each step of the preparation are referred to Example 1, except that the reaction starting material used is 2'-methoxycytidine.

[0174] The obtained 2'-methoxycytidine triphosphate was detected, and the nuclear magnetic resonance data were: 1 H NMR(400MHz,D2O)δ7.96(d,J=0.8Hz,1H),6.05(d,J=0.8Hz,1H),5.96(d,J=1. 2Hz, 1H), 5.88 (d, J = 3.6Hz, 1H), 4.72 (t, 1H), 4.03-4.51 (m, 5H), 3.40 (s, 3H).

[0175] Example 21 2'-ethoxycytidine triphosphate

[0176] This example provides a chemically modified cytidine triphosphate, wherein the chemically modified cytidine triphosphate is 2'-ethoxycytidine triphosphate. The reaction conditions of each step of the preparation are referred to Example 1, except that the reaction starting material used is 2'-ethoxycytidine.

[0177] The obtained 2'-ethoxycytidine triphosphate was tested, and the nuclear magnetic resonance data were as follows: 1 H NMR(400MHz,D2O)δ7.97(d,J=0.8Hz,1H),6.67(s,2H),6.03(d,J=0.8Hz,1H),5 .53(d,J=3.6Hz,1H),4.70(t,1H),4.02-4.52(m,5H),3.87(q,2H),1.19(t,3H).

[0178] Example 22 DNA template preparation

[0179] Using the plasmid encoding luciferase as a template, DNA polymerase is used in a PCR tube. The specific steps are as follows:

[0180] 1) The luciferase DNA template was prepared by PCR in a 96-well PCR instrument.

[0181] The PCR product should include at least:

[0182] A) a promoter sequence (T7 promoter);

[0183] B) a 5'UTR containing at least one Kozak sequence;

[0184] C) 3'UTR;

[0185] D) Luciferase coding sequence;

[0186] E) Poly A tail (poly Atail).

[0187] The specific sequences involved in this example are shown in Table 1

[0188] Table 1

[0189] name sequence T7 promoter taatacgactcactatagg(SEQ ID No:1) 5'UTR SEQ ID No:2 3'UTR SEQ ID No:3 Luciferase SEQ ID No:4 Poly A tail aaaaaaaaaaaaaaaaaaaaaaaaaaaaa(SEQ ID No:5) Primer F taatacgactacctagggggctggccggtacctgagctc(SEQ ID No:6) Primer R ctccccctgaacctgaaacata(SEQ ID No:7)

[0190] SEQ ID No:2:

[0191] ggcctaactggccggtacctgagctcgctagcctcgaggatatcaagatctggcctcggcggccaagctt.

[0192] SEQ ID No:3:

[0193] taattctagagtcgggcggccggccgcttcgagc.

[0194] SEQ ID No:4:

[0195]

[0196] The DNA template was amplified according to the following reaction system: reaction volume, 50 μL (reaction volume of a single tube, multiple tubes were reacted at one time), and the specific reaction system is shown in Table 2.

[0197] Table 2

[0198] Components volume Phanta Max High-Fidelity DNA Polymerase 1μL 2× Phanta Max Buffer 25μL pGL4.10(luc2)vector 0.05μL Primer F 1μL Primer R 1μL dNTPs 1μL water 20.95μL

[0199] The reaction program was as follows: pre-denaturation at 95°C for 1 min, denaturation at 95°C for 15 s, annealing at 52°C for 5 s, extension at 72°C for 2 min, for a total of 32 cycles; and final extension at 72°C for 5 min.

[0200] After the reaction is completed, the reaction solution is combined in a 1.5 mL Tube tube, and 2 μL is taken for DNA agarose gel electrophoresis to confirm the success of the reaction (agarose gel electrophoresis detection conditions: 2% agarose, 5 V / min, 30 min).

[0201] The reaction product was purified using HiPure Gel Pure DNA Mini Kit. The purification process is as follows:

[0202] (1) Briefly centrifuge the PCR product.

[0203] (2) Add an equal volume of Buffer GDP and mix by inversion.

[0204] (3) Place the HiPure DNA column in a collection tube, transfer the mixture to the DNA column, and centrifuge at 12,000 g for 30-60 seconds. Discard the filtrate and place the column back in a 2 mL centrifuge tube. Add 600 μL of buffer DW2 (diluted with anhydrous ethanol) to the column and centrifuge at 12,000 g for 30-60 seconds.

[0205] (4) Discard the filtrate and put the column back into a 2 mL centrifuge tube. Add 600 μL of buffer DW2 (diluted with anhydrous ethanol) to the column and centrifuge at 12,000 g for 30-60 seconds. Discard the filtrate and put the column back into a 2 mL centrifuge tube and centrifuge at 12,000 g for 2 minutes.

[0206] (5) Put the column back into a 1.5 mL centrifuge tube, add 15-30 μL of elution buffer to the center of the column membrane, leave at room temperature for 2 minutes, and centrifuge at 12,000 g for 1 minute. Discard the column, use a NanoDrop Spectrophotometer to detect the concentration of the template DNA, as well as the 260 / 280 and 260 / 230 ratios, and then store the DNA at -20°C.

[0207] Example 23 In vitro transcription synthesis of mRNA in which chemically modified nucleosides globally replace natural nucleosides

[0208] The prepared chemically modified nucleosides are used to globally replace natural nucleosides to synthesize chemically modified mRNA. The chemically modified cytidine triphosphate includes modifications as follows: N4-acetyl, N4-propionyl, N4-butyryl, N4-pentanoyl, N4-hexanoyl, N4-benzoyl, 5-methyl-N4-acetyl, 5-methyl-N4-butyryl, 5-methyl-N4-hexanoyl, 5-methyl.

[0209] The synthesis of chemically modified mRNA was achieved by in vitro transcription using T7 RNA polymerase. Taking a 50 μL reaction system as an example, the components shown in Table 3 were added sequentially into a 0.2 mL PCR reaction tube.

[0210] Table 3

[0211]

[0212]

[0213] CTP* is cytosine triphosphate or chemically modified cytosine triphosphate.

[0214] Cap Analogue# is a commercially available cap analog; in this example, 3'-O-Me-m provided by New England Biolabs was used. 7 -G(5')ppp(5')G RNA Cap Structure Analog, catalog number is S1411S.

[0215] The reaction procedure is as follows: Turn on the thermostat's hot cover and set it to 60°C. Click the thermostat reaction system, 37°C, 2-4h. After the incubation is completed, the mRNA purification method is as follows:

[0216] (1) Add 1 μL DNase I (RNase-free) to each 50 μL reaction system and incubate at 37°C for 15 minutes to digest the DNA template in the system.

[0217] (2) Add 2.5 μL of ethylenediaminetetraacetic acid disodium salt solution (500 mM) to each 50 μL reaction system and incubate at 65°C for 10 minutes.

[0218] (3) Suspend the cellulose solution in the elution solution to prepare an elution solution of 0.2 g cellulose / mL (reference for preparation method: A Facile Method for the Removal of dsRNA Contaminants from In Vitro Transcribed mRNA, Molecular Therapy Nucleic Acids, 2019, 15, 26-35). Put the DNA adsorption column in a 2 mL receiving tube (Guangzhou Meiji Biotechnology, DNA / RNA small amount adsorption column, catalog number M021), then take 630 μL of the suspension into the DNA column and vortex for 2 hours for activation.

[0219] (4) The activated cellulose suspension was centrifuged at 13,000 g for 1 minute, the filtrate was discarded, and 500 μL of the elution solution was added to resuspend. The in vitro transcription reaction mixture solution was then added to the DNA column and vortexed for 30 minutes.

[0220] (5) Centrifuge the DNA column at 13,000 g for 1 min, collect the filtrate, add it to a new activated DNA column (activation step as described in step 3), and vortex for 30 min.

[0221] (6) Centrifuge the DNA column at 13,000 g for 1 minute, collect the filtrate, and then transfer the filtrate to a new 1.5 mL nuclease-free centrifuge tube pre-chilled on ice.

[0222] (7) Pre-cool anhydrous isopropanol and 3 M sodium acetate solution on ice, then add 500 μL of isopropanol and 50 μL of sodium acetate to the centrifuge tube in (6), gently invert to mix, and then centrifuge at 14,000 g for 10 min at 4°C.

[0223] (8) Remove the supernatant solution, add 300 μL of 4°C precooled anhydrous ethanol to the centrifuge tube, and then centrifuge at 14,000 g at 4°C for 10 min.

[0224] (9) Remove the supernatant solution and air-dry the precipitate at room temperature for 30 minutes.

[0225] (10) The obtained mRNA product was dissolved in 20-50 μL of nuclease-free water, and the concentration of the purified mRNA was measured using a NanoDrop Spectrophotometer, and the ratios of 260 / 230 and 260 / 280 were also measured simultaneously.

[0226] (11) Take 500 ng of purified mRNA and perform agarose gel electrophoresis to detect the integrity of its fragments.

[0227] (12) Store the mRNA solution at -80°C.

[0228] Fig.38 It is a schematic diagram of the in vitro transcription results of chemically modified C series nucleoside triphosphates. In the figure, lane 1 is natural cytosine, lane 2 is 5-methylcytosine, lane 3 is 5-methyl-N4-acetylcytosine, lane 4 is 5-methyl-N4-butyrylcytosine, lane 5 is 5-methyl-N4-hexanoyl, lane 6 is 5-methyl-N4-benzoylcytosine, lane 7 is N4-acetylcytosine, lane 8 is N4-propionylcytosine, lane 9 is N4-butyrylcytosine, and lane 10 is mRNA of N4-hexanoylcytosine; lane M is an RNA molecular weight standard.

[0229] If the DNA template obtained by PCR does not contain polyadenylic acid series (poly A), a tailing reaction is required. The specific steps of the tailing reaction are as follows:

[0230] Prepare the reaction system as shown in Table 7 in a 0.2 mL PCR Tube at room temperature; Table 4 is the tailing reaction system, with a total volume of 20 μL.

[0231] Table 4

[0232]

[0233]

[0234] The reaction procedure is as follows: set the thermostatic reactor with a lid temperature of 60°C and incubate at 37°C for 30 minutes. After the incubation is completed, the tailed mRNA is purified by the cellulose method described above, and then the mRNA tail length and the integrity of the tailed mRNA fragment are detected by agarose gel electrophoresis.

[0235] Example 24 In vitro transcription synthesis of mRNA using chemically modified nucleosides in combination with N1-methylpseudouridine to globally replace natural nucleosides

[0236] The same method as in Example 23 was used, except that in this example, chemically modified cytosine triphosphate was mixed with N1-methyl pseudouridine triphosphate in a 50 / 50 ratio, and the natural cytosine triphosphate was replaced globally to perform in vitro transcription synthesis of luciferase mRNA. The combinations used included N4-acetylcytosine triphosphate / N1-methyl pseudouridine triphosphate=50 / 50, N4-butyrylcytosine triphosphate / N1-methyl pseudouridine triphosphate=50 / 50, and N4-hexanoylcytosine triphosphate / N1-methyl pseudouridine triphosphate=50 / 50.

[0237] Example 25 Expression efficiency of chemically modified mRNA in cells

[0238] Synthesize mRNA containing a single type of cytidine modification or mRNA modified by a single type of modified cytidine combined with N1 methyl pseudouridine encoding luciferase, and detect its expression efficiency in cells; after transfecting it into cells, translate it into the target protein luciferase, and then use luciferin as a substrate to use the translated luciferase to oxidize luciferin chemiluminescence, and use a microplate reader to detect its luminescence intensity, so as to determine the translation efficiency of natural and chemically modified mRNA. In this example, the chemically modified mRNA is transfected into HEK 293T cells and HeLa cells, respectively, and the luminescence intensity is detected.

[0239] The specific steps for transfecting HEK 293T cells with chemically modified mRNA are as follows:

[0240] (1) Cell transfection

[0241] About 24 hours after inoculation of human embryonic kidney 293T cells (purchased from the Chinese Academy of Sciences Cell Bank), observe the cell status in the 24-well plate, and the confluence is 70%. In the biological safety cabinet, prepare 90% (volume percentage) DMEM + 10% (volume percentage) FBS culture medium. Discard the culture medium in the well plate 30 minutes before transfection, and add 500 μL of fresh culture medium, i.e. 90% (volume percentage) DMEM + 10% (volume percentage) FBS culture medium, to each well.

[0242] (2) Preparation of transfection system

[0243] Take 50μL Opti-MEM, add 800ng mRNA, and mix well. Also prepare a mixed solution of 2μL Lipofectamine2000 and 50μL Opti-MEM, and incubate at room temperature for 10 minutes. Then add the Lipofectamine 2000 mixture to the mRNA mixture, mix well, and incubate for 20 minutes. Add the mixed solution to the well plate. Change the medium 6h after transfection, aspirate the old culture medium, and replace each well with 500μL fresh culture medium, that is, 90% (volume percentage) DMEM + 10% (volume percentage) FBS culture medium. Harvest 24h / 48h after transfection. Aspirate the old culture medium and wash once with 1mL PBS. Aspirate the PBS, digest the cells with 200 μL 1× Cell Lysis Buffer (Abcam, ab152163) for 5 minutes, then blow down the cells with a pipette, collect them in a 1.5 mL centrifuge tube, centrifuge at 14000 g for 10 minutes at 4°C, and then take 170 μL of the supernatant solution in a new 1.5 mL centrifuge tube for luciferin luminescence detection.

[0244] The experimental steps for detecting luminescence with an ELISA reader are as follows:

[0245] Add 50 μL of the above-extracted protein solution containing luciferase to a 96-well plate, then incubate at room temperature for 10 minutes, then add 50 μL of Luciferase Assay Reagent (Promega, E1483), pipette evenly, and complete the luminescence intensity detection on a microplate reader within 5 minutes. Set up two replicate wells for each sample.

[0246] Fig.39 This is the expression efficiency diagram of transcribed mRNA transfected HEK 293T cells 24 hours later. The horizontal axis in the figure is the sample type. In the figure:

[0247] 1 indicates luciferase mRNA transcribed using natural nucleoside triphosphates as substrates;

[0248] 2 indicates luciferase mRNA transcribed using N4-acetylcytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0249] 3 indicates luciferase mRNA transcribed using N4-propionyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0250] 4 indicates luciferase mRNA transcribed using N4-butyryl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0251] 5 indicates luciferase mRNA transcribed using N4-pentanoyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0252] 6 represents luciferase mRNA transcribed using N4-hexanoyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0253] 7 represents luciferase mRNA transcribed using N4-benzoylcytidine triphosphate instead of natural cytidine triphosphate as substrate.

[0254] from Fig.39 It can be seen that the translation efficiency of luciferase mRNA with global replacement of N4-propionylcytosine, N4-butyrylcytosine, N4-pentanoylcytosine, and N4-hexanoylcytosine in HEK 293T cells is higher than that of luciferase mRNA transcribed from natural cytosine, among which the translation efficiency of luciferase mRNA with global replacement of N4-butyrylcytosine can be enhanced to 2.91 times, proving that chemically modified cytosine can effectively enhance the translation efficiency of transcribed mRNA.

[0255] The steps of chemically modified mRNA transfection into HeLa cells were carried out according to the method of transfecting HEK 293T cells. Fig.41 This is the expression efficiency diagram of transcribed mRNA transfected HEK 293T cells 24 hours later. In the figure:

[0256] 1 indicates luciferase mRNA transcribed using natural nucleoside triphosphates as substrates;

[0257] 2 indicates luciferase mRNA transcribed using N4-acetylcytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0258] 3 indicates luciferase mRNA transcribed using N4-propionyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0259] 4 indicates luciferase mRNA transcribed using N4-butyryl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0260] 5 indicates luciferase mRNA transcribed using N4-pentanoyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0261] 6 represents luciferase mRNA transcribed using N4-hexanoyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0262] 7 represents luciferase mRNA transcribed using N4-benzoylcytidine triphosphate instead of natural cytidine triphosphate as substrate.

[0263] from Fig.41 It can be seen that the translation efficiency of luciferase mRNA with global replacement of N4-propionylcytosine, N4-butyrylcytosine, N4-pentanoylcytosine and N4-hexanoylcytosine in HeLa cells is higher than that of luciferase mRNA transcribed from natural cytosine, among which the translation efficiency of luciferase mRNA with global replacement of N4-propionylcytosine, N4-butyrylcytosine and N4-pentanoylcytosine can be enhanced by more than 10 times, proving that chemically modified cytosine can effectively enhance the translation efficiency of transcribed mRNA.

[0264] Fig.40 This is a graph showing the expression efficiency of mRNA transcribed by N1-methyl pseudouridine and modified cytidine after transfection into HEK 293T cells for 24 hours. In the graph:

[0265] 1 indicates luciferase mRNA transcribed using natural nucleoside triphosphates as substrates;

[0266] 2 indicates luciferase mRNA transcribed using N4-acetylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate as substrates;

[0267] 3 indicates luciferase mRNA transcribed using N4-propionylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate as substrates;

[0268] 4 represents luciferase mRNA transcribed with N4-butyrylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate instead of natural cytidine triphosphate as substrates;

[0269] 5 indicates luciferase mRNA transcribed with N4-pentanoylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate instead of natural cytidine triphosphate as substrates;

[0270] 6 represents luciferase mRNA transcribed with N4-hexanoylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate instead of natural cytidine triphosphate as substrates;

[0271] 7 represents luciferase mRNA transcribed using N1-methylpseudouridine triphosphate instead of uridine triphosphate as substrate.

[0272] As can be seen from the figure, compared with natural cytosine, the translation efficiency of luciferase mRNA transcribed by combining N4-acetylcytidine triphosphate and N1-methyl pseudouridine triphosphate, N4-propionylcytidine triphosphate and N1-methyl pseudouridine triphosphate in HEK 293T cells was enhanced by 2.63-3.32 times. The mRNA with global replacement of N1-methyl pseudouridine triphosphate alone can achieve an enhanced translation efficiency of 1.87 times.

[0273] Fig.42 This is a graph showing the expression efficiency of mRNA transcribed using N1-methyl pseudouridine and modified cytidine after transfection into HeLa cells for 24 hours. In the graph:

[0274] 1 indicates luciferase mRNA transcribed using natural nucleoside triphosphates as substrates;

[0275] 2 indicates luciferase mRNA transcribed using N4-acetylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate as substrates;

[0276] 3 indicates luciferase mRNA transcribed using N4-propionylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate as substrates;

[0277] 4 represents luciferase mRNA transcribed with N4-butyrylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate instead of natural cytidine triphosphate as substrates;

[0278] 5 indicates luciferase mRNA transcribed with N4-pentanoylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate instead of natural cytidine triphosphate as substrates;

[0279] 6 represents luciferase mRNA transcribed with N4-hexanoylcytidine triphosphate and N1-methylpseudouridine triphosphate instead of natural cytidine triphosphate and uridine triphosphate instead of natural cytidine triphosphate as substrates;

[0280] 7 represents luciferase mRNA transcribed using N1-methylpseudouridine triphosphate instead of uridine triphosphate as substrate.

[0281] As can be seen from the figure, compared with natural cytosine, the translation efficiency of luciferase mRNA transcribed by N4-acetylcytidine triphosphate, N4-propionylcytidine triphosphate, N4-butyrylcytidine triphosphate, and N4-pentanoylcytidine triphosphate in HeLa cells was enhanced by 1.66 to 10.82 times after the combination of N4-acetylcytidine triphosphate, N4-propionylcytidine triphosphate, N4-butyrylcytidine triphosphate and N1-methyl pseudouridine. The translation efficiency of mRNA replaced by N1-methyl pseudouridine alone was enhanced by 9.5 times.

[0282] Example 26 Stability of chemically modified mRNA in cells

[0283] An mRNA encoding luciferase containing a single type of cytidine modification was synthesized and its stability in cells was tested; its stability refers to the relative amount of residual intact mRNA extracted after the mRNA was transfected into the cells for a certain period of time.

[0284] In this example, the chemically modified mRNA was transfected into HEK 293T cells and HeLa cells, respectively, and qPCR detection was performed.

[0285] The specific steps for chemically modified mRNA transfection into HEK 293T cells and qPCR detection are as follows:

[0286] Cell inoculation and cell transfection steps are described in Example 25. 3h after transfection, the culture medium was discarded, the cells were rinsed once with 1×PBS, and then the PBS washing solution was aspirated. 200μL TransZol Up lysis solution (Quanshi Jin Bio, ET1111) was added, and it was placed horizontally for a moment to evenly distribute the lysis solution on the cell surface and lyse the cells, and then the cells were blown off with a pipette. After that, the lysis solution was transferred to a centrifuge tube, and it was blown repeatedly with a pipette until there was no obvious precipitation in the lysate, and it was left to stand at room temperature for 5 minutes. 40μL chloroform was added, and it was shaken violently for 30 seconds, and then incubated at room temperature for 3 minutes. Centrifuged at 10000g for 15 minutes at 4°C, at which time the sample was divided into 3 layers, the upper layer was a colorless aqueous phase, and the middle layer and the lower layer were pink organic phases. At this time, RNA was in the aqueous phase, and 90μL of colorless aqueous phase was extracted with a pipette, transferred to a new centrifuge tube, 90μL of anhydrous ethanol was added, and gently inverted to mix evenly. Transfer the obtained precipitate and solution to the centrifuge column, centrifuge at 12000g for 30 seconds at room temperature, and discard the effluent. Add 100μL CB9, centrifuge at 12000g for 30 seconds at room temperature, discard the effluent, and repeat once. Add 100μL WB9, centrifuge at 12000g for 30 seconds at room temperature, discard the effluent, and repeat once. Then centrifuge at 12000g for 2 minutes at room temperature to completely remove the residual anhydrous ethanol. Place the centrifuge column in the RNase-free Tube, add 20μL nuclease-free water to the center of the centrifuge column, and let it stand at room temperature for 1 minute. Then centrifuge at 12000g for 1 minute at room temperature to elute RNA. The total RNA obtained was quantified using NanoDrop. Then take 1μg of total RNA and synthesize cDNA using Hifair 1st Strand cDNA Synthesis Kit (gDNA digester plus) (Yishen Bio, 11139ES10). The obtained cDNA was quantified by NanoDrop, and 500 ng of cDNA was taken and then amplified by fluorescence quantitative amplification using Hieff UNICONUniversal Blue qPCR SYBR Green Master Mix (Yisheng Biotechnology, 11184ES08). The fluorescence quantitative PCR instrument used was qTower. The stability of mRNA was calculated by converting the obtained Ct value into 2 -Δ The relative value is calculated.

[0287] Fig.43 The qPCR results of the stability of chemically modified mRNA in HEK 293T cells are shown in the figure:

[0288] 1 indicates luciferase mRNA transcribed using natural nucleoside triphosphates as substrates;

[0289] 2 indicates luciferase mRNA transcribed using N4-acetylcytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0290] 3 indicates luciferase mRNA transcribed using N4-propionyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0291] 4 indicates luciferase mRNA transcribed using N4-butyryl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0292] 5 indicates luciferase mRNA transcribed using N4-pentanoyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0293] 6 represents luciferase mRNA transcribed using N4-hexanoyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0294] 7 represents luciferase mRNA transcribed using N4-benzoylcytidine triphosphate instead of natural cytidine triphosphate as substrate.

[0295] from Fig.43 It can be seen that the stability of luciferase mRNA with global replacement of N4-propionylcytosine, N4-butyrylcytosine, N4-pentanoylcytosine, and N4-hexanoylcytosine in HEK 293T cells is higher than that of luciferase mRNA transcribed from natural cytosine, proving that global replacement of chemically modified cytosine can enhance the stability of transcribed mRNA in cells.

[0296] The steps of chemically modified mRNA transfection into HeLa cells and qPCR detection were carried out according to the method of transfecting HEK 293T cells. Fig.44 This is the qPCR result of the stability test of chemically modified mRNA in HeLa cells. In the figure:

[0297] 1 indicates luciferase mRNA transcribed using natural nucleoside triphosphates as substrates;

[0298] 2 indicates luciferase mRNA transcribed using N4-acetylcytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0299] 3 indicates luciferase mRNA transcribed using N4-propionyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0300] 4 indicates luciferase mRNA transcribed using N4-butyryl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0301] 5 indicates luciferase mRNA transcribed using N4-pentanoyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0302] 6 represents luciferase mRNA transcribed using N4-hexanoyl cytidine triphosphate instead of natural cytidine triphosphate as a substrate.

[0303] from Fig.44 It can be seen that the stability of luciferase mRNA with global replacement of N4-propionyl cytosine, N4-pentanoyl cytosine and N4-hexanoyl cytosine in HEK 293T cells is higher than that of luciferase mRNA transcribed from natural cytosine, proving that global replacement of chemically modified cytosine can enhance the stability of transcribed mRNA in cells.

[0304] Example 27 Immunogenicity of chemically modified mRNA in cells

[0305] Synthesize mRNA encoding luciferase containing a single type of cytidine modification and test its immunogenicity. Transfect the mRNA into macrophages RAW264.7, and then detect the immune factors produced by RAW264.7 cells 24 hours after transfection, including tumor necrosis factor α and interleukin 6. The specific steps are as follows:

[0306] The cell inoculation and cell transfection steps are described in Example 25. The cells used in this example are macrophages RAW264.7. 24h after cell transfection, the cells were digested with 200μL 1×Cell Lysis Buffer (Abcam, ab152163) for 5 minutes, and then the cells were blown down with a pipette, collected in a 1.5mL centrifuge tube, centrifuged at 14000g for 10 minutes at 4°C, and then 170μL of supernatant solution was taken in a new 1.5mL centrifuge tube. Take 50μL of the extracted protein solution, add 100μL BCA protein quantification kit solution (Yisheng Biology, 20201ES76), then blow evenly with a pipette, incubate at 30°C for 30 minutes, and then detect its absorbance at 562nm with Epoch Microplate Reader. The total protein concentration extracted was calculated according to the standard curve. The immunogenicity of luciferase mRMA was expressed as the amount of cytokines, including tumor necrosis factor α and interleukin 6, secreted after luciferase mRMA stimulated RAW264.7 cells.

[0307] The amount of cytokines was quantified by Western blotting, and the specific steps were as follows:

[0308] Take 20 μg of total protein sample, add 1 / 5 volume of 6×Protein Loading Buffer (All-Gold Biotechnology, DL101), then boil at 95℃ for 10 minutes, and then cool to 4℃ on ice. Centrifuge briefly, and then separate all samples with 12% SDS-PAGE gel. Then transfer the sample to a PVDF membrane, and then block the membrane with 5% skim milk at room temperature for 2h, and then rinse the membrane with 1× TBST Buffer 3 times, 20mL each time. Then incubate with the corresponding primary antibody diluted 1:3000 (the primary antibody is the primary antibody of the target protein and the primary antibody of the internal reference protein, so there are two types, including: recombinant Anti-TNF alpha antibody, EPR19147, Abcam and Antib-beta Actin antibody, AC-15, Abcam) at 4℃ overnight. Then rinse the membrane with 1× TBST Buffer 3 times, 20mL each time. After that, the corresponding secondary antibodies (Goat Anti-Rabbit IgG H&L HRP, ab6721, Abcam and Goat Anti-Mouse IgG H&L HRP, ab6728, Abcam) diluted 1:5000 were incubated for 1 hour, and then the membrane was rinsed 3 times with 1× TBST Buffer, 10 mL each time. Then, enhanced ECL chemiluminescence exposure reagent (Yisheng Bio, 36222ES60) was prepared for chemical exposure. The relative content of the produced cytokines was expressed as the intensity of the extracted bands.

[0309] Fig.45 The Western blot results of the immunogenicity test of chemically modified mRNA in RAW264.7 cells are shown in the figure:

[0310] 1 represents buffer solution PBS;

[0311] 2 indicates luciferase mRNA transcribed using natural nucleoside triphosphates as substrates;

[0312] 3 indicates luciferase mRNA transcribed using N4-acetylcytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0313] 4 indicates luciferase mRNA transcribed using N4-propionylcytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0314] 5 indicates luciferase mRNA transcribed using N4-butyryl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0315] 6 indicates luciferase mRNA transcribed using N4-pentanoyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0316] 7 indicates luciferase mRNA transcribed using N4-hexanoyl cytidine triphosphate instead of natural cytidine triphosphate as substrate;

[0317] 8 represents luciferase mRNA transcribed using N4-benzoylcytidine triphosphate instead of natural cytidine triphosphate as substrate.

[0318] As can be seen from the figure, compared with the luciferase mRNA transcribed from natural cytosine, the luciferase mRNA with global replacement of chemically modified cytosine did not show weakened immunogenicity in RAW264.7 cells.

[0319] In summary, the present invention provides a chemically modified cytidine and a chemically modified cytidine triphosphate, and globally replaces the natural cytidine triphosphate with the chemically modified cytidine triphosphate to obtain a chemically modified mRNA, wherein the chemically modified mRNA has higher translation efficiency both in a cell-free system and in cells, and is more stable.

[0320] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. A chemically modified cytosine nucleoside, It is characterized in that The chemically modified cytosine nucleoside is selected from a compound having a structure as shown in Formula VIII, a salt thereof or an isomer thereof: Among them, R 1 is selected from hydrogen, acetyl, halogen-substituted acetyl, propionyl, halogen-substituted propionyl, butyryl, halogen-substituted butyryl, valeryl, halogen-substituted valeryl, hexanoyl, halogen-substituted hexanoyl, octanoyl, decanoyl, benzoyl, 4-methoxybenzoyl or 4-nitrobenzoyl; R 2 is selected from hydrogen, methyl, methoxy, fluoro, chloro, bromo, iodo or nitrile; R 3 Selected from hydroxy, hydrogen, fluorine, methoxy, ethoxy or methoxymethyl ether.

2. A chemically modified cytosine triphosphate, It is characterized in that The chemically modified cytosine triphosphate is selected from a compound having a structure as shown in Formula I, a salt thereof or an isomer thereof: Among them, R 1 is selected from hydrogen, acetyl, halogen-substituted acetyl, propionyl, halogen-substituted propionyl, butyryl, halogen-substituted butyryl, valeryl, halogen-substituted valeryl, hexanoyl, halogen-substituted hexanoyl, octanoyl, decanoyl, benzoyl, 4-methoxybenzoyl or 4-nitrobenzoyl; R 2 Selected from hydrogen, methyl, methoxy, fluoro, chloro, bromo, iodo, nitrile; R 3 Selected from hydroxy, hydrogen, fluorine, methoxy, ethoxy or methoxymethyl ether.

3. The method for preparing the chemically modified cytosine triphosphate according to claim 2, It is characterized in that The preparation method comprises: (1) subjecting the hydroxyl group of the compound of formula II to a hydroxyl protection reaction to obtain a compound of formula III; (2) reacting the compound of formula III with an acid anhydride or an acid chloride to obtain a compound of formula IV; (3) subjecting the protecting group of the compound of formula IV to complete deprotection reaction to obtain a compound of formula V; (4) reacting the compound of formula V with a chlorinating agent to obtain a compound of formula VI; (5) reacting the compound of formula VI with tributylammonium pyrophosphate to obtain a compound of formula VII; (6) subjecting the compound of formula VII to a quenching reaction to obtain a compound of formula I; 4. The method for preparing chemically modified cytosine triphosphate according to claim 3, It is characterized in that In step (1), tert-butyldimethylsilyl chloride is used to carry out hydroxyl protection reaction; Preferably, in step (2), the acid anhydride is selected from acetic anhydride, propionic anhydride, butyric anhydride, valeric anhydride, caproic anhydride, caprylic anhydride, capric anhydride or benzoic anhydride; Preferably, in step (2), the acyl chloride is selected from 4-methoxybenzoyl chloride or 4-nitrobenzoyl chloride.

5. The method for preparing the chemically modified cytosine triphosphate according to claim 3 or 4, It is characterized in that In step (3), tetrabutylammonium fluoride is used to carry out a complete deprotection reaction; Preferably, in step (4), the chlorination agent is selected from phosphorus oxychloride.

6. A chemically modified nucleic acid, It is characterized in that The chemically modified nucleic acid is prepared by using the chemically modified cytosine triphosphate as described in claim 2 for global replacement, or the chemically modified cytosine triphosphate and N1-methyl pseudouridine triphosphate are used in combination to replace the natural cytosine triphosphate in the mRNA; Preferably, the nucleic acid further contains pseudouridine, N-methylpseudouridine, 5-methoxyuridine or 2-thiouridine.

7. The chemically modified nucleic acid according to claim 6, It is characterized in that The nucleic acid at least comprises: A) a promoter sequence; B) a 5'UTR containing at least one Kozak sequence; C) 3'UTR; D) a coding sequence consisting of linked nucleotides; E) Poly A tail.

8. The method for preparing a chemically modified nucleic acid according to claim 6 or 7, It is characterized in that The preparation method comprises: Using four ribonucleotides, adenosine triphosphate, guanosine triphosphate, uridine triphosphate and chemically modified cytosine triphosphate, as raw materials, PCR reaction is carried out with DNA as a template under the catalysis of RNA polymerase to synthesize chemically modified nucleic acids.

9. The method for preparing a chemically modified nucleic acid according to claim 8, It is characterized in that The RNA polymerase is T7 RNA polymerase; The PCR reaction system includes: DNA template, RNase inhibitor, T7 RNA polymerase, RNA polymerase buffer, adenosine triphosphate, guanosine triphosphate, uridine triphosphate and chemically modified cytosine triphosphate and 5' cap structure.

10. Use of any one or a combination of at least two of the chemically modified cytidine according to claim 1, the chemically modified cytidine triphosphate according to claim 2, the method for preparing the chemically modified cytidine triphosphate according to any one of claims 3 to 5, the chemically modified nucleic acid according to claim 6 or 7, or the method for preparing the chemically modified nucleic acid according to claim 8 or 9 in the preparation of an mRNA drug.